http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014200325-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1999280264f90e7502b512f1bd695728 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-098 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02 |
| filingDate | 2014-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd3ed69b70914fb889b7cd8f018cdc9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f950789db5e5e929372102ae9ad1489d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2e205979d7e234d324f4ccf9696460a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8b5cc6909098661b6161d461e961aa7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1432a45be6e3715df9c49269aee3df0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fdfdff2ff5f99fd9a104b2de22c1752a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00d4a65af4dca3931b6bd3bf0930908b |
| publicationDate | 2014-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2014200325-A2 |
| titleOfInvention | Consortium of the recombinant influenza a viruses flu-ns1-124- l7/l12-h5n1, flu-ns1-124-omp16-h5n1, flu-ns1-124-l7/l12-h1n1 and flu-ns1- 124-omp16-h1n1, family ortomyxoviridae, genus influenzavirus, expressing brucella immunodominant proteins destined to generate a vaccine against brucellosis |
| abstract | This invention relates to the fields of biotechnology, veterinary science and public health, and describes a vector vaccine which can be used to prevent brucellosis. The essence of the invention is that reverse genetics methods have been used to construct novel, genetically-stable recombinant influenza viral vectors based on the influenza A viral vectors Flu-NSl-124-L7/L12- H5N1, Flu-NSl-124-Omp16-H5Nl, Flu-NSl-124-L7/L12-HlNl and Flu-NSl-124-Omp16- H1N1 (of the subtypes H5N1 and H1N1) that contain the genetic sequences of the Brucella proteins L7/L12 (ribosomal) or Omp16 (outer membrane) inserted into the viral NS1 gene, which express these Brucella proteins in vivo and are safe in cattle. Our studies showed that this vaccine candidate in cattle induced a strong antigen-specific T-cell immune response, and most importantly provided a high level of protectiveness comparable to the commercial B. abortus n S19 vaccine and superior to the B. abortus n S19 vaccine in combination with Montanide Gel01 adjuvant. Furthermore it is shown that the developed vaccines can effectively differentiate vaccinated animals from infected animals. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111638329-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113637703-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109116035-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113637703-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111638329-B |
| priorityDate | 2013-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 153.